Overview

Efficacy of ORM-12741 for Prevention of Raynaud's Phenomenon

Status:
Terminated
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
Raynaud's phenomenon (RP) is a disorder of the digital blood vessels resulting in episodic impairment of blood flow. During an attack of RP which commonly affects the hands and feet these arteries contract briefly which limits the blood flow (this is called a vasospasm) and deprived of blood the skin turns white then blue. The aim of this study is to prove the concept that ORM-12741 can prevent these blood vessel spasms.
Phase:
Phase 2
Details
Lead Sponsor:
Orion Corporation, Orion Pharma